Vericel Corporation is a publicly traded American biopharmaceutical company that develops and markets cellular therapies for sports medicine and severe burn care. The company's product portfolio includes MACI, an autologous cellularized scaffold product for the repair of symptomatic, full-thickness cartilage defects of the knee in adults; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep dermal or full thickness burns. Vericel was founded in 1989 and is headquartered in Cambridge, Massachusetts.